Inactive Instrument

Highlights Edge Therapeutics Inc Nasdaq

Equities

US2798701098

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Empire Metals targets key milestones in Australia	Mar. 27	AN
PDS Biotechnology Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
PDS Biotechnology Corporation Announces Publication of Preclinical Research	Mar. 13	CI
Pds Biotech Announces CFO Changes	Nov. 28	CI
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of Pds0101-Based Triple Combination Therapy in Advanced Hpv16-Positive Cancer Patients	Nov. 09	CI
PDS Biotechnology Corporation Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients At ESMO	23-10-23	CI
PDS Biotechnology Corporation Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer	23-10-11	CI
PDS Biotechnology Corporation Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA	23-10-03	CI
PDS Biotechnology Corporation Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies	23-09-20	CI
NetScientific's PDS suffers wider loss as R&D costs mount	23-08-14	AN
PDS Biotechnology Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate Versatile-003 Trial	23-08-14	CI
PDS Biotechnology Corporation to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA in Head and Neck Cancer Patients at ESMO Congress 2023	23-07-25	CI
Pds Biotech Announces Acceptance of Abstract on Combination of Pds0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute At Cytokines 2023	23-07-17	CI
PDS Biotechnology Corporation Strengthens Intellectual Property Portfolio Governing A Combination of VersamuneÂ®? and PDS0301	23-07-11	CI
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the Versatile-002 Trial Evaluating Pds0101 and Keytruda in Head and Neck Cancer	23-06-14	CI
PDS Biotechnology Corporation Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with Keytruda (Pembrolizumab) for Head and Neck Cancer Patients	23-05-25	CI
Pds Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of Versatile-002 Phase 2 Clinical Trial in Advanced Hpv16 Positive Head and Neck Cancer	23-05-18	CI
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Edge Therapeutics Inc Nasdaq

Equities

US2798701098

Highlights

Filters